Public Sector Pension Investment Board Sells 2,500 Shares of Balchem Co. (NASDAQ:BCPC)

Public Sector Pension Investment Board reduced its stake in shares of Balchem Co. (NASDAQ:BCPC) by 3.5% in the 3rd quarter, Holdings Channel reports. The firm owned 68,812 shares of the basic materials company’s stock after selling 2,500 shares during the quarter. Public Sector Pension Investment Board’s holdings in Balchem were worth $12,111,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its holdings in Balchem by 32.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock worth $29,929,000 after acquiring an additional 47,036 shares during the period. Janus Henderson Group PLC grew its holdings in Balchem by 21.3% during the 1st quarter. Janus Henderson Group PLC now owns 18,059 shares of the basic materials company’s stock worth $2,795,000 after acquiring an additional 3,176 shares during the period. Tidal Investments LLC acquired a new stake in Balchem during the 1st quarter worth about $265,000. Cetera Advisors LLC acquired a new stake in Balchem during the 1st quarter worth about $321,000. Finally, DekaBank Deutsche Girozentrale grew its holdings in Balchem by 3.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 53,300 shares of the basic materials company’s stock worth $8,175,000 after acquiring an additional 2,000 shares during the period. 87.91% of the stock is owned by institutional investors.

Balchem Stock Performance

Shares of BCPC opened at $179.69 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90. The stock has a 50-day moving average of $174.30 and a 200-day moving average of $167.17. The company has a market cap of $5.84 billion, a PE ratio of 48.30, a P/E/G ratio of 5.46 and a beta of 0.65. Balchem Co. has a one year low of $120.87 and a one year high of $186.03.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. HC Wainwright increased their price target on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, November 4th. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research note on Monday, October 28th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.